Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down – Should You Sell?

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) gapped down before the market opened on Thursday . The stock had previously closed at $35.74, but opened at $31.68. Collegium Pharmaceutical shares last traded at $31.7870, with a volume of 139,638 shares traded.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Finally, Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $57.50.

Collegium Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The firm has a market capitalization of $1.00 billion, a PE ratio of 15.20 and a beta of 0.73. The firm’s 50 day moving average price is $34.95 and its 200-day moving average price is $37.24.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.Collegium Pharmaceutical’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.68 EPS. On average, research analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Large investors have recently added to or reduced their stakes in the stock. Group One Trading LLC purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth about $28,000. Caitong International Asset Management Co. Ltd increased its stake in Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 427 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 318 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.